Global Biosimilars Partnering Terms and Agreements 2010 to 2020

December 2020 •
140 pages •
Report ID: 5580129 •
Format: PDF

Summary
Table of contents

The Global Biosimilars Partnering Terms and Agreements 2010 to 2020 report provides an understanding and access to the Biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in Biosimilars partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Biosimilars partnering contract documents
Top Biosimilars deals by value

The Global Biosimilars Partnering Terms and Agreements report provides an understanding and access to the Biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Biosimilars partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Biosimilars technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual Biosimilars deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:
• What is actually granted by the agreement to the partner company?

• What exclusivity is granted?

• What are the precise rights granted or optioned?

• What is the payment structure for the deal?

• How are sales and payments audited?

• What is the deal term?

• How are the key terms of the agreement defined?

• How are IPRs handled and owned?

• Who is responsible for commercialization?

• Who is responsible for development, supply, and manufacture?

• How is confidentiality and publication managed?

• How are disputes to be resolved?

• Under what conditions can the deal be terminated?

• What happens when there is a change of ownership?

• What sublicensing and subcontracting provisions have been agreed?

• Which boilerplate clauses does the company insist upon?

• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

• Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of Biosimilars dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Biosimilars dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Biosimilars deals since 2010. Deals are listed by headline value, signed by big pharma, most active Biosimilars dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Biosimilars dealmaking with a brief summary followed by a comprehensive listing of Biosimilars deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Biosimilars partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Biosimilars partnering deals signed and announced since Jan 2010. The chapter is organized by specific Biosimilars technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Biosimilars partnering company A-Z, deal type definitions and Biosimilars partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Biosimilars partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Biosimilars technologies and products.

Report scope
Global Biosimilars Partnering Terms and Agreements 2010 to 2020 is intended to provide the reader with an in-depth understanding and access to Biosimilars trends and structure of deals entered into by leading companies worldwide.

Global Biosimilars Partnering Terms and Agreements 2010 to 2020 includes:
Trends in Biosimilars dealmaking in the biopharma industry since 2010
Analysis of Biosimilars deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life Biosimilars deals
Access to over 160 Biosimilars deal records and contract documents where available
The leading Biosimilar deals by value since 2010
Most active Biosimilars dealmakers since 2010
The leading Biosimilars partnering resources

In Global Biosimilars Partnering Terms and Agreements 2010 to 2020, the available contracts are listed by:
Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy and technology target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Ahmad helps you find the right report:

+1 718 618 4302
Contact by email

FAQ

Testimonials

The market research advisor answered my questions quickly and professionally. ReportBuyer's team did their best to ensure that I felt comfortable before making the investment to purchase the report.

Cristian Nunez

Director of Corporate Development Chugach Alaska Corporation

My overall experience with ReportBuyer today has been very positive, and I must thank you for your patience (...). Also, the sample you sent me and the explanations provided were very helpful.

D. Lescuyer

Executive Vice President Oral Business at Skyepharma

The research specialist was very helpful, and proposed the best content for my needs. ReportBuyer also offered a great follow-up, thanks for everything !

P. Thompson

EMEA Managing Director

We were satisfied with the support that ReportBuyer's team provided. Thanks to their recommendations, the report we purchased provided exactly what we want.

Y. Wang

Business Analyst

We didn't have time to do the research internally, and thanks to ReportBuyer's team we were able to find the appropriate data.

S. Chen

Research Coordinator

I was impressed by the customer service: it was fast, responsive, and 100% professional !

D. Krivan

Market Research Analyst

The research specialist provided prompt and helpful service. He also followed up to ensure I had all the information to deliver my business development plan.

C. Adams

Senior Business Development Manager